Redeye briefly comments on Initiator Pharma’s announcement that the EPO has granted a European patent covering pudafensine for FSD. We view this as a strategically important milestone that strengthens the company’s intellectual property position in women’s health, particularly given the ongoing phase IIa study in vulvodynia. The patent enhances long-term commercial optionality and supports Initiator’s diversification beyond ED, reinforcing the value proposition of pudafensine ahead of upcoming clinical milestones.
LÄS MER
